FibroBiologics, Inc. (SG0.F)
| Previous Close | 8.50 |
| Open | 8.45 |
| Bid | 8.30 x N/A |
| Ask | 8.60 x N/A |
| Day's Range | 8.45 - 8.45 |
| 52 Week Range | 6.25 - 12.29 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 289.26M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
FibroBiologics to Present at the BIO International Convention 2024
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a corporate update on recent business and clinical developments at the 2024 BIO International Conve
- GlobeNewswire
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
Next-generation cell therapies to target chronic diseasesHOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology. This agreement comes ahead of entering into an anticipated master
- GlobeNewswire
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a patent from the Australian Patent Office (Patent Number 2017207445) covering the proprietary method using a particular cellular blend for the regeneration
